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doi:10.1016/j.gmbhs.2011.10.001Abstract Immunization is the most cost effective weapon for disease prevention in devel-
oping countries, and advanced molecular and genetic technologies are making new types of
vaccines feasible. Here, the utility of both in vitro and in vivo methods to assess the release
pattern of chitosan microspheres containing tetanus toxoid (TT) vaccine were evaluated. TT
was stabilized and encapsulated in chitosan (TTCH) with a water-in-oil-in-water (W/O/W)
multiple emulsion method using sucrose as a protein stabilizer. The TTCH prepared was smooth
and spherical in shape with a diameter of around 10 mm. The in vitro release efficiency of TTCH
was evaluated by differing stabilizer (sucrose) concentration (5%, 7%, 10% and 12% w/v) for
a period of 70 days. The antigen release rates from the microspheres were determined by
enzyme-linked immunosorbent assay. In these TTCH microspheres, a 10% w/v sucrose concen-
tration gave good sustained antigen delivery for the period of 70 days. Based on the results of
in vitro release, the in vivo studies were carried out using alum-adsorbed TT (from the Central
Research Institute) as the standard. The antibody level was measured after 6 months, 9 months
and finally, with one booster dose, after 12 months. In these in vivo studies, the TTCH antibody
level rose up to 3.5 IU/mL of guinea pig serum; this compared with 2 IU/mL of guinea pig serum
using the alum-adsorbed TT after 12 months with a second booster dose. The TTCH approach
would be helpful to replace the existing adjuvant alum in the future.
Copyright ª 2011, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.ogy Centre, Anna University of Technology Coimbatore, Jothipuram post, Coimbatore - 641047,
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10 There are many advantages to using chitosan orThe majority of currently available vaccines require several
booster doses to induce effective immunity and this results
in significant compliance problems, particularly in the
developing world. This is particularly true for immunization
with several vaccines; for example, the triple vaccine
against diphtheria, pertussis and tetanus, widely used in
the Expanded Program on Immunization, demands admin-
istration of the vaccines at repeated intervals of 4e6
weeks, three times. These multiple injection patterns have
limitations because a percentage of children who receive
the first dose do not turn up for the second or third dose, so
do not complete the immunization schedule and are not
fully immunized.1
Currently, vaccine development is experiencing another
wave of tremendous progress with the aid of modern
immunology techniques and biotechnology. Various vaccine
targets have been identified; alongside prophylactic
disease resistance, vaccine development is ongoing for
a number of cancers and AIDS.2 Moreover, safe and effica-
cious vaccines have been developed, such as subunit, live-
vector based and DNA vaccines.
Tetanus remains a major killer in developing countries,
with more than 500,000 deaths per year from neonatal
tetanus alone, largely due to the logistical difficulty of
delivering the two to three doses of vaccine required to
confer protection for pregnant women, whose immunity
can be passively transferred to the fetus.3
Aluminum phosphate and aluminum hydroxide are the
currently approved adjuvants for human vaccination and are
widely used for vaccines at present.4 In recent years, there
have been various attempts to demonstrate new improved
techniques to induce a higher level of immunogenicity
following parenteral and/or oral administration.5 One
approach has been to use biodegradable polymer technology
to simplify a sustained release antigen following parenteral
administration, which, it is envisaged, will minimize the
number of injections given in the normal regimen.6 Our main
aim in the present research is to develop a single-dose
vaccine to reduce the multiple injections administered to
infants during the first 3 months [the present tetanus toxoid
(TT) vaccination schedule is onedosepermonth for thefirst 3
months]. With respect to our primary goal, the single-dose
vaccine has been developed successfully and, upon further
investigation, reduces even the need for booster doses. The
original aimof thedevelopedvaccinedeliverywas todevelop
a single dose to replace the initial multiple doses, not the
booster dose; the booster dose is to raise the antibody level
later on. Our current investigation is focused on reducing, or
completely removing, the booster dose by increasing the
initial load of antibody.
Chitosan is derived by the deacetylation of chitin, which
is a polymer of D-glucosamine and N-acetyl-D-glucosamine.
Chitosan is well-known for its hydrophilic, biocompatible,
biodegradable and non-toxic properties.7e9 Chitosan
suspensions or micro- and nanoparticles have been repor-
ted to have immune stimulating activities, such as
increasing accumulation and activation of macrophage
and polymorphonuclear cells, promoting resistance to
infections by microorganisms, and inducing cytokinechitosan microspheres for vaccine delivery. First, chitosan
can open the intercellular tight junctions and favor the
paracellular transport of macromolecules. Second, chitosan
nano- and microspheres are suitable for controlled drug and
vaccine release. Third, chitosan nano- and microspheres
are most efficiently taken up by phagocytotic cells. Thus
chitosan and its derivatives could induce strong systemic
and mucosal immune responses against antigens.8,10
Immunizations with various antigens co-administered with
chitosan produce both systemic and local immune
responses. In a phase I clinical study, intranasal immuni-
zation with an influenza vaccine formulated with soluble
chitosan glutamate showed positive effects.11
Materials and methods
Chitosan (0.15 Pa.s viscosity grade, 80% deacetylation) was
purchased from the Central Institute of Fisheries Technology
(Cochin, India). Tween 80 and Span 80 were purchased from
Fluka (Sigma Aldrich, Buchs, Switzerland). TT (molecular
weight, 150 kDa), with a limit of flocculation (Lf) content of
1250/mL, and the standard tetanus antitoxin were received
as gifts from the Central Research Institute (CRI, Kasauli,
H.P., India). Sucrose and sodium tripolyphosphate (TPP)
were purchased from Sigma Aldrich (St. Louis, MO, USA). All
other chemicals and reagents used were of analytical grade.
Preparation of TT encapsulated chitosan
microspheres
A water-in-oil-in-water (W/O/W) multiple emulsion tech-
nique was used to prepare chitosan microspheres by
following the previously described procedure with slight
modifications.12 Four batches of microspheres were
prepared by altering the stabilizer (sucrose) concentration
(5%, 7%, 10% and 12% w/v). The dispersion phase was
prepared by mixing 50 mL of linseed oil and 10% of Tween
80 at 1700 rpm for 10 minutes. To this, 3 mL of 1% stabilized
chitosan gel were mixed separately to form a water-in-oil
emulsion. To the above emulsion, 2 mL of alum-free TT
(1250 Lf units/mL), which was previously stabilized with
various concentrations of sucrose, was added and the stir-
ring continued. After 2 hours, 2 mL of 5% w/v of TPP was
introduced drop wise and stirring continued for a further 2
hours. Another 2 ml of TPP was then added and the stirring
continued for another 2 hours. Finally, the suspension of
microspheres was centrifuged at 15,000 rpm to remove the
oil layer and the pellets were separated. The pellets were
washed five times with 5 mL of toluene then washed three
times with 5 mL of acetone. The microspheres were sus-
pended in 10 mL of acetone and dried at room tempera-
ture. The dried microspheres were stored in sealed glass
vials in a vacuum desiccator.
Physicochemical characterization of the
microspheres
The morphological examination of the microspheres was
performed using a scanning electronmicroscope (SEM; JSM-T
Stabilized tetanus toxoid in chitosan microspheres 93220 A, Jeol, Japan). The microspheres were mounted on to
metal stubs using double sided carbon adhesive tape. After
being vacuum-coated with gold palladium to a thickness of
200e300 A˚, the microspheres were examined with the SEM
at 15 or 10 kV (Fig. 1).
Estimation of TT content in chitosan microspheres
A weighed (10 mg) quantity of microspheres were powdered
in an agate mortar and the TT was extracted with 6 mL of
phosphate buffered saline (PBS) at pH 7.4, in screw-capped
vials, by rotating the tubes head to tail in a hematology
mixer for 7 days.12 The total antigen content in the extract
was determined by enzyme-linked immunosorbent assay
(ELISA). The complete extraction was obtained by further
treating the microspheres with 5% v/v hydrogen chloride in
ethanol for another 2 days. Placebo microspheres (without
the antigen) containing sucrose were used as a control.
In vitro release study
In vitro release studies of the prepared microspheres with
various concentrations of sucrose (5%, 7%, 10% and 12% w/v)
were carried out separately in conical flasks by taking
50 mg of microspheres and 50 mL of PBS with Tween 80 (pH
7.4) and incubating them at 37 C on a constant shaking
mixer.12 The contents of the vial were withdrawn and
centrifuged at 5000 rpm for 5 minutes at predetermined
time intervals (Days 0, 2, 4, 8, 12, 16, 21, 28, 35, 42, 49, 56,
63 and 70). The TT concentrations in the supernatants were
determined by ELISA. Placebo microspheres without the
antigen were used as a control.
ELISA for TT
TT antigenicity was measured by ELISA as described by
Johansen et al, with slight modifications.13 Briefly, flat-
bottom 96-well Nunc immuno microtiter plates were filled
with 100 mL of 2 IU/mL of horse anti-tetanus immunoglob-
ulin G in 0.05 M carbonate buffer of pH 9.6 overnight. TheFigure 1 Scanning electron micrograph of the chitosan
microspheres encapsulating the tetanus toxoid, prepared with
10% sucrose.plates were washed three times with 300 mL of PBS con-
taining 0.05% Tween 20. After this, a two-fold dilution
series of sample and reference TT samples were prepared
using PBS with 0.5% bovine serum albumin (BSA). The plates
were held at room temperature for 24 hours followed by
the addition of peroxidase-labeled sheep anti-TT serum (in
PBS with 0.5% BSA) at room temperature for 2 hours.
Finally, 100 mL of 0.2 mg/mL peroxidase substrate, 2,20-
azino-bis(3-ethylbenzthiazoline-6-sulfonate), in 100 mM
sodium phosphate solution was added to the plates. The
reaction was stopped by the addition of 50 mL per well of
5 N sulfuric acid. The plates were read on an ELISA reader
after 30 minutes at a wavelength of 405 nm.In vivo immunogenicity study
An ideal batch of chitosan microspheres encapsulated with
TT (TTCH) was tested for immunizing potency and its
antibody response to tetanus was measured in international
units (IU/mL of serum). The vaccine combinations used for
the immunization of the guinea pigs either with the booster
dose or without the booster dose is categorized in Table 1.
The animal studies were carried out based on the institu-
tional animal ethical committee recommendations from
CRI.
Each immunization combination (Table 1) was per-
formed on nine guinea pigs (250e350 g). The booster dose,
wherever indicated, was given not later than 4 weeks from
the date of the primary immunization. Blood samples were
collected about 2 weeks after the booster dose. The
immune guinea pig sera were collected and tested in mice
and guinea pigs for the measurement of tetanus antibodies.
The potency test was conducted as per the standards of
National Control Laboratories (CRI) and Indian Pharmaco-
poeia (IP, 1985).14 Bleeding of the immunized guinea pigs
was done by cardiac puncture using a 20-gauge needle. The
blood samples were collected in sterile glass tubes and kept
in a slanting position so as to allow the serum to ooze out of
the clotted bottle. Then these tubes were centrifuged at
2000 rpm for 45 minutes. The supernatant immune serum
from each tube was transferred to another sterile 5 mL vial
using sterile Pasteur pipettes and numbered. The sera
samples were inactivated at 55C in a water bath for
20 minutes, before they were tested for tetanus antibodies
by the antibody induction method.Table 1 The various combinations used for in vivo
immunogenicity study.
Combination Primary immunization Booster
1 TTCH TTCH
2 TTCH No booster
3 CRIa TTCH
4 TTCH CRIa
5 CRIa CRIa
6 CRIa No booster
CRIZ Central Research Institute; TTCHZ tetanus toxoid
encapsulated in chitosan.
a Alum-adsorbed tetanus toxoid from the CRI.
Figure 2 Release profiles of tetanus toxoid-loaded chitosan
microspheres prepared with different concentrations of
sucrose.
Table 2 In vitro release study of TTCH microspheres
prepared by differing sucrose (stabilizer) concentration.
Day Cumulative percentage release for each
sucrose concentration
5% 7% 10% 12%
0 0 0 0 0
2 0 0 50.00 0
4 20.00 0 65.00 20.00
8 32.00 20.00 66.50 22.00
12 33.20 32.00 66.65 32.20
16 33.32 43.20 76.67 33.22
21 43.33 44.32 77.67 33.32
28 44.33 65.43 77.77 33.33
35 44.43 66.54 87.78 43.33
42 44.44 66.65 88.78 44.33
49 44.44 87.67 88.88 44.43
56 44.44 88.77 88.89 44.44
63 54.44 88.88 98.89 44.44
70 55.44 88.89 99.89 44.44
TTCHZ tetanus toxoid encapsulated in chitosan.
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Compared with the other adjuvants, alum is relatively
weak15 and may not be able to sufficiently enhance the
immune response toward a poorly immunogenic antigen.
Physicochemical and morphological differences in alum
vaccines owing to batchebatch variation and aging16 can
cause variability in the immune response that must be
overcome by repeated injections, defeating the purpose of
including the adjuvant in the first place. In many studies,
aluminum-adsorbed vaccines did not show any advantage
over soluble preparations for the booster or secondary
response.17e19
Physical characterization of TT loaded chitosan
microspheres
Four batches of TTCH microspheres were prepared and the
effect of stabilizer concentration on in vitro release char-
acteristics was evaluated. All the microspheres were
prepared with a size range between 1 mm and 50 mm
(Fig. 1). These size ranges were selected to define the role
of macrophage uptake as an essential requirement for
single point immunization.20 In microspheres of 2e8 mm,
more than 90% of the particles have a diameter less than
5 mm, so they will be taken up by antigen presenting cells21
whereas with microspheres with a diameter of less than
2 mm there will be further enhanced cellular uptake due to
the submicron size ranges of polymer particles.22 With
regard to the size range and percent of microspheres
greater than10 mm, those prepared with 10% w/v of sucrose
showed a more uniform distribution and optimum
morphological characteristics, that is, no roughness, no
porosity, no clumping and high sphericity (data not shown).
In vitro release study
The in vitro release of the antigen by TTCH microspheres
stabilized with sucrose at different concentrations (5%, 7%,
10% and 12% w/v) was compared with microspheres
prepared without the sucrose stabilizer. The TTCH micro-
spheres with 10% w/v of sucrose showed a good release
pattern, i.e., about 8e10 % of encapsulated antigen was
released in the first 3e5 days. Similarly 7e9% of the antigen
was released within the first day of incubation (Fig. 2 and
Table 2) by the batch prepared with 7% w/v sucrose. All the
remaining batches showed irregular or lower initial release.
Among the batches prepared in chitosan microspheres, the
batch prepared with 10% w/v sucrose showed the lowest
release rate, which could be considered as an appropriate
release pattern for mucosal immunization.
In vivo immunogenicity study
The level of tetanus-specific antibody present in the serum
collected from guinea pigs immunized with TTCH and
tetanus toxoid adsorbed on to aluminum phosphate gel
(from CRI) is given in Table 3.
TTCH administered to nine guinea pigs as a primary
immunization with one booster dose gave rise to immune
sera containing a maximum antibody level of 2 IU/mL ofguinea pig serum. When no booster was given, the level of
antibody was found to be 1 IU/mL of guinea pig serum. The
sera samples collected from guinea pigs primarily immu-
nized with alum-adsorbed TT and given a booster dose of
TTCH contained a maximum antibody level of 1.5 IU/mL of
guinea pig serum. When the primary immunization was
done with TTCH and alum-adsorbed TT given as a booster
dose, the antibody level also rose, to 1.5 IU/mL of guinea
pig serum. When the control-adsorbed TT was given for
both the primary and booster inoculations, the antibody
level in the immune sera was found to be 1.5 IU/mL of
guinea pig serum. The antibody level was found to be only
1 IU/mL of guinea pig serum when no TT adsorbed booster
given.
As per the I.P. requirement, all the combinations of
primary immunization and booster dose passed the potency
testdthe minimum requirement as per the I.P. is that at
Table 3 The antibody levels of immune guinea pig sera after first bleeding.
Combinations Primary
immunization
Booster Antibody levels (IU/mL)
0.05 0.5 1 1.5 2 2.5
1 Chitosan (encap) Chitosan (encap) U U U U U d
2 Chitosan (encap) No booster U U U d d d
3 CRIa Chitosan (encap) U U U U d d
4 Chitosan (encap) CRIa U U U U d d
5 CRIa CRIa U U U U d d
6 CRIa No booster U U U d d d
CRIZ Central Research Institute; TTCHZ tetanus toxoid encapsulated in chitosan.
a Alum-adsorbed tetanus toxoid from the CRI.
Table 4 The antibody level of immune guinea pig sera after 6 months of primary immunization.
S.no Primary
immunization
Booster Antibody levels (IU/mL)
0.05 0.5 1 1.5 2 2.5 3 3.5 4
1 TTCH TTCH U U U U U U d d d
2 CRIa CRIa U U U U U d d d d
CRIZ Central Research Institute; TTCHZ tetanus toxoid encapsulated in chitosan.
a Alum-adsorbed tetanus toxoid from the CRI.
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antibody level of 0.05 IU/mL and at least one third of the
guinea pig sera contains 0.5 IU/mL.
The highest level of antibody, 2.5 IU/mL of guinea pig
serum, was found to be in the sera of guinea pigs immu-
nized with TTCH as the primary and booster dose. When the
control alum-adsorbed TT vaccine was given as the primary
and booster dose, this gave rise to a maximum antibody
level of 2 IU/mL of guinea pig serum. However, as per the
I.P. requirement, the two combinations, 1 and 5 (see
Table 1), passed the potency test. The results are shown in
Table 4.
After 9 months, the same guinea pigs were again bled
and their sera tested for specific antibody level. Guinea
pigs vaccinated according to combination 1 still continued
to have a maximum antibody level of 1 IU/mL of guinea pig
serum. However, with combination 5, the maximum
potency level was found to be 0.5 IU/mL of guinea pig
serum. These findings show that, after a period of 9
months, there is gradual decline in the tetanus antibody
levels. The results are shown in Table 5.
When given TTCH as the primary vaccination and booster
(combination 1), the antibody level rose up to 3.5 IU/mL of
guinea pig serum after the second booster dose. InTable 5 The antibody level of immune guinea pig sera after 9
S. nos Primary
immunization
Booster
0.05 0.5
1 TTCH TTCH U U
2 CRIa CRIa U U
CRIZ Central Research Institute; TTCHZ tetanus toxoid encapsulate
a Alum-adsorbed tetanus toxoid from the CRI.combination 5, with the alum-adsorbed TT as the primary
vaccination and booster, after the second booster the
potency was found to be 2 IU/mL of guinea pig serum,
which is not even comparable to the results from combi-
nation 1. The results are shown in Table 6.Discussion
In our study, the main objective was to evaluate the suit-
ability and potential of chitosan polymeric systems as
adjuvants for the TT vaccine that are easy to deliver and
elicit a long-lasting immune response. The actual size of
the individual microspheres was in the range of 1e50 mm
and a few of them were more than 50 mm. During the
preparation of chitosan microspheres, it is necessary to use
discordant solvents, which may degrade proteins. Exposing
the microspheres to physiological environments may also
destabilize the protein molecules.1,3 It is thus necessary to
stabilize the protein during both the encapsulation process
and release from the microspheres. Therefore, the micro-
spheres were co-encapsulated with a cheap potential
protein stabilizer, sucrose. It has also been hypothesized
that a protein stabilizer can shield the antigen from themonths of primary immunization.
Antibody levels (IU/mL)
1 1.5 2 2.5 3 3.5 4
U U U U d d d
U U U d d d d
d in chitosan.
Table 6 The antibody level of immune guinea pig sera after 1 year of primary immunization with 2nd booster dose.
S.nos Primary
immunization
Booster Antibody levels (IU/mL)
0.05 0.5 1 1.5 2 2.5 3 3.5 4
1 TTCH TTCH U U U U U U U U d
2 CRIa CRIa U U U U U d d d d
CRIZ Central Research Institute; TTCHZ tetanus toxoid encapsulated in chitosan.
a Alum-adsorbed tetanus toxoid from the CRI.
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thus preventing protein-interface exposure to deleterious
solvent effects.23 The loading efficiency of chitosan
microspheres containing 10% sucrose was increased from
80e90%, whereas the lowest TT payload was observed
without sucrose. This could be due to inactivation of the TT
at the water-oil interface (the first emulsification step).24
The TT release pattern from the chitosan microspheres
stabilized with sucrose at different concentrations (5%, 7%,
10% and 12% w/v) was compared with microspheres without
sucrose. TTCH microspheres without sucrose released only
5% of the loaded TT and no further release was observed
over the following 70 days. Mechanical forces employed in
the first emulsion might also cause protein structural
perturbations, which often result in irreversible aggrega-
tion.25 A potential approach to increase the TT concentra-
tion and loading during emulsification is by using a protein
stabilizer (sucrose). This resulted in good stabilization upon
TT encapsulation in and release from microspheres made
using a W/O/W method.26 The protein stabilizer prevents
denaturation at the water-oil interface, which is reflected
in an augmented cumulative percentage (88.88% for TTCH)
release. In addition, sucrose has good solubility in aqueous
media. The protein stabilizer (sucrose) concentration was
directly proportional to the percentage release of TT from
the microspheres. To this end, the higher concentration of
sucrose (12%, w/v) increased the initial burst release of TT
within 5 days. But the 10% sucrose mix increased the sus-
tained release of TT up to 70 days as compared to 12%
sucrose. In conclusion, 10% w/v sucrose was found to be
a specific, sensitive, reproducible and stable antigen during
the encapsulation and release system.
In the immunogenicity study, microspheres with 10% w/v
sucrose were used. In this study, the levels of antibody
were equal or higher when measured 6 months, 9 months
and 12 months after primary immunization. The results of
in vivo studies indicate that TTCH microspheres have
potential application in the field of vaccine delivery and
could be an appropriate choice for the development of
a single-dose vaccine against tetanus in the future.Conclusions
In the present studies, we have selected chitosan as
a suitable adjuvant, and 10% w/v of sucrose as a stabilizer
lead to better in vitro release characteristics. The potency
of TTCH was tremendously increased after 1 year with
a second booster dose when compared to standard alum-
adsorbed TT (CRI). Further studies are required toinvestigate in greater detail the use of chitosan and its
derivatives for their pharmaceutical applications.Acknowledgments
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